{"id":654893,"date":"2023-06-09T10:12:02","date_gmt":"2023-06-09T10:12:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=654893"},"modified":"2023-06-09T10:12:02","modified_gmt":"2023-06-09T10:12:02","slug":"hemophilia-a-market-to-observe-stupendous-growth-during-the-forecast-period-20222032-delveinsight-key-companies-biomarin-roche-apcintex-novo-nordisk-sanofi-alnylam-pfizer-sangamo","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/hemophilia-a-market-to-observe-stupendous-growth-during-the-forecast-period-20222032-delveinsight-key-companies-biomarin-roche-apcintex-novo-nordisk-sanofi-alnylam-pfizer-sangamo_654893.html","title":{"rendered":"Hemophilia A Market to Observe Stupendous Growth During the Forecast Period (2022-2032) – DelveInsight | Key Companies – BioMarin, Roche, ApcinteX, Novo Nordisk, Sanofi, Alnylam, Pfizer, Sangamo"},"content":{"rendered":"
\n
\"Hemophilia<\/a><\/div>\n
\n
Delveinsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n
The Hemophilia A market size in the 7MM was USD 8,510 million in 2021 and is projected to grow during the forecast period (2022-2032).<\/div>\n

As per DelveInsight, the Hemophilia A Market is anticipated to evolve immensely in the coming years owing to the rise in the prevalent population of Hemophilia A, the rise in healthcare spending across the world, the expected entry of premium price assets such as gene therapy, siRNA and bispecific antibodies, and the expected readily uptake of recently approved therapies.  Several major Pharma giants are thoroughly working toward the development of new treatment therapies for Hemophilia A, in order to provide better relief for the symptoms and hence improve the Quality of life (QoL) of the affected patients.<\/em><\/p>\n

DelveInsight’s “Hemophilia A Market Insights, Epidemiology, and Market Forecast 2032<\/strong>” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Hemophilia A market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).<\/p>\n

The report covers emerging Hemophilia A drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Hemophilia A treatment practice\/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. <\/p>\n

\"Hemophilia<\/p>\n

Hemophilia A: An Overview<\/strong><\/p>\n

Hemophilia A is a genetic bleeding disorder in which an individual lacks or has low levels of proteins named clotting factor VIII. Without enough factor VIII, the blood cannot clot properly to control bleeding. Although it is passed down from parents to children, about 1\/3 of cases found have no previous family history.<\/p>\n

It is caused by an inherited X-linked recessive trait, with the defective gene located on the X chromosome. Females have two copies of the X chromosome. So if the factor VIII gene on one chromosome does not work, the gene on the other chromosome can do the job of making enough factor VIII.<\/p>\n

People with hemophilia A bleed longer than other people. Bleeds can occur internally, in joints and muscles, or externally, from minor cuts, dental procedures, or injuries. The frequency of the bleeds and the severity of those bleeds depend on how much FVIII a person produces naturally. Normal levels of FVIII range from 50% to 150%. Levels below 50% – or half of what is needed to form a clot – determine a person’s symptoms.<\/p>\n

Hemophilia A Market Key Facts<\/strong><\/p>\n